ANTI-OVARIAN CANCER PROPERTIES OF RU-486

RU-486 的抗卵巢癌特性

• 批准号: 7960311
• 负责人: Carlos Marcelo Telleria
• 金额: $ 3.47万
• 依托单位: UNIVERSITY OF SOUTH DAKOTA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-16 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7960311
• 关键词: Biomedical Research; Clinical; Computer Retrieval of Information on Scientific Projects Database; Contraceptive Agents; Disease; Drug usage; Feasibility Studies; Funding; Goals; Grant; Growth; Growth Inhibitors; Human; Institution; Label; Laboratories; Malignant Neoplasms; Malignant neoplasm of ovary; Medical; Mifepristone; Mus; Pharmaceutical Preparations; Politics; Property; Publishing; RU-486; Research; Research Infrastructure; Research Personnel; Resources; Source; South Dakota; Steroids; United States National Institutes of Health; abortion; anticancer research; cancer cell; design; preclinical study; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The laboratory of Dr. Carlos Telleria is studying the anti-ovarian cancer properties of the synthetic steroid mifepristone, also known as RU-486. The anti-cancer activity is totally unrelated to the contraceptive properties (of mifepristone). These studies are pre-clinical studies of off-label uses for this drug. The utility of this drug for other medical illnesses has been underexplored and jeopardized by anti-abortion politics. The overall goal of the research in the laboratory is to study the feasibility of utilizing this synthetic steroid, originally designed for contraceptive purposes, for the treatment of ovarian cancer. Experiments from Dr. Telleria's laboratory, which have been supported through SD BRIN pilot grants, have recently been published in the June 1, 2007 issue of Clinical Cancer Research. They reveal that mifepristone is a potent inhibitor of the growth of ovarian cancer, demonstrated utilizing human ovarian cancer cells maintained in culture and mice carrying ovarian cancer disease. The growth inhibition effect of mifepristone for ovarian cancer is not related to the antiprogesterone activity that claims its contraceptive properties.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 Carlos Telleria 博士的实验室正在研究合成类固醇米非司酮（也称为 RU-486）的抗卵巢癌特性。 抗癌活性与（米非司酮）的避孕特性完全无关。 这些研究是该药物标签外用途的临床前研究。 这种药物治疗其他疾病的效用尚未得到充分探索，并受到反堕胎政治的危害。 实验室研究的总体目标是研究利用这种最初用于避孕目的的合成类固醇治疗卵巢癌的可行性。 Telleria 博士实验室的实验得到了 SD BRIN 试点资助的支持，最近发表在 2007 年 6 月 1 日出版的《临床癌症研究》杂志上。他们利用培养中的人类卵巢癌细胞和携带卵巢癌疾病的小鼠证明，米非司酮是卵巢癌生长的有效抑制剂。米非司酮对卵巢癌的生长抑制作用与其声称具有避孕作用的抗孕酮活性无关。